Antiepileptic drug development for "therapeutic orphans".
Epilepsy is the most common serious neurological disorder among children. Excluding the elderly, the incidence of epilepsy is highest among children. About half of children with epilepsy have epilepsy syndromes that have unique onset in childhood. Clinical drug trials of antiepileptic drugs (AEDs) among children have been primarily performed using drugs developed for the larger adult partial epilepsy market. The current AED drug development system essentially renders children with epilepsy "therapeutic orphans" who can only benefit from AED development if a drug developed for adult partial epilepsy happens to also be effective for a pediatric epilepsy syndrome. The rapid evolution of different seizure types and childhood epilepsy syndromes, and rapid changes in baseline neurological status, make distinguishing clinical changes due to study drugs in clinical trials and the natural history of the epilepsy syndrome difficult. Unique ethical issues (e.g., informed consent), practical and logistical issues (e.g., serum AED level monitoring with microassay methods), as well as major financial and regulatory disincentives for the pharmaceutical industry are additional barriers to need-based AED development for children. A government-funded pediatric epilepsy group or consortium to conduct clinical trials similar to the successful Children's Oncology Group (COG) and regulations plus financial incentives that encourage the pharmaceutical industry to develop AEDs specifically for children are needed.
Trevathan
Edwin
E
Pediatric Epilepsy Center, Department of Neurology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, Missouri 63110-1093, USA.
D000927:Anticonvulsants; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000145:classification / Q000188:drug therapy; D006801:Humans; D009965:Orphan Drug Production; D013678:Technology, Pharmaceutical
D000927:Anticonvulsants